Last reviewed · How we verify
conventional analgesic regimen
conventional analgesic regimen is a Analgesic combination regimen Small molecule drug developed by Ain Shams University. It is currently in Phase 3 development for Acute and chronic pain management (specific indication not detailed in available information).
A conventional analgesic regimen combines multiple pain-relieving medications to provide additive or synergistic pain control through different mechanisms of action.
A conventional analgesic regimen combines multiple pain-relieving medications to provide additive or synergistic pain control through different mechanisms of action. Used for Acute and chronic pain management (specific indication not detailed in available information).
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | conventional analgesic regimen |
|---|---|
| Sponsor | Ain Shams University |
| Drug class | Analgesic combination regimen |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | Phase 3 |
Mechanism of action
Conventional analgesic regimens typically combine medications such as nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, and/or opioids to target pain through multiple pathways including cyclooxygenase inhibition, central nervous system pain modulation, and opioid receptor activation. This multimodal approach aims to improve pain relief while potentially reducing the required dose of individual agents and associated adverse effects.
Approved indications
- Acute and chronic pain management (specific indication not detailed in available information)
Common side effects
- Gastrointestinal upset
- Nausea
- Dizziness
- Constipation
- Hepatotoxicity (acetaminophen-related)
Key clinical trials
- Opioid Free and Opioid Based Anesthesia in Elective Lumbar Spine Surgery
- Postoperative Analgesia and Ventilation After Cardiac Surgery
- Clinical Application of Dynamic Multimodal Analgesia Regimen After Perianal Abscess Surgery (NA)
- Effect of Anterior Disc Displacement With Reduction on Postoperative Pain After Root Canal Treatment (NA)
- Duloxetine RCT on Postop TKA Outcomes (PHASE4)
- Efficacy of Auricular Acupuncture Therapy in the Prevention of CIPN in Breast Cancer (NA)
- TIPS Block vs. IV Analgesia for Postoperative Pain After Knee Arthroscopy (NA)
- An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- conventional analgesic regimen CI brief — competitive landscape report
- conventional analgesic regimen updates RSS · CI watch RSS
- Ain Shams University portfolio CI
Frequently asked questions about conventional analgesic regimen
What is conventional analgesic regimen?
How does conventional analgesic regimen work?
What is conventional analgesic regimen used for?
Who makes conventional analgesic regimen?
What drug class is conventional analgesic regimen in?
What development phase is conventional analgesic regimen in?
What are the side effects of conventional analgesic regimen?
Related
- Drug class: All Analgesic combination regimen drugs
- Manufacturer: Ain Shams University — full pipeline
- Therapeutic area: All drugs in Pain Management
- Indication: Drugs for Acute and chronic pain management (specific indication not detailed in available information)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing